Kisqali savings card: as little as $0 a prescription with commercial insurance

How to pay the least

Cash price

$9,540+ for 30 tablets

Pharmacies pay about this for Kisqali; you’d pay more.

Ask your pharmacy for Kisqali’s cash price, and one or two other pharmacies too.
Kisqali’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify Novartis Patient Assistance Foundation (NPAF). Patients must have a household income of less than or equal to $81,760 (for a household size of two) to be considered for NPAF. Or call 1-800-277-2254.

See if you qualify

No generic is sold yet.

Compare every option

Brand nameKisqali

Authorized genericribociclib

Regular genericribociclib

What you’d pay

At least$9,540for 30 tablets; pharmacies pay this

Not soldThere isn’t one

Not soldNone sold yet

Same as Kisqali?

The original

–

Brand nameThe maker’s card

KISQALI Co-Pay Plus

Savings card from Novartis

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $0 a prescription

Or call 1-866-433-8000.

In the maker’s words

“Eligible patients with private insurance may pay as little as $0…”

From the maker’s offer on us.kisqali.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Kisqali itself, from the same company, sold without the brand name, and usually for less. For now Kisqali is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

No generic is sold yet. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

HR-positive, HER2-negative breast cancer

What the FDA label says

KISQALI is a kinase inhibitor indicated:

in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence.
for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with:
- an aromatase inhibitor as initial endocrine-based therapy; or
- fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy.

Source: the FDA label for Kisqali (Novartis Pharmaceuticals Corporation), July 1, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to your pharmacy.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/kisqali/